Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAC-14028 cream in mild to moderate atopic dermatitis
NCT02965118Phase 3Completed
- Sponsor
- Amorepacific Corporation
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing PAC-14028 cream 1.0% with Vehicle (2 arms). Primary endpoint: Success rate of Investigator's Global Assessment at 8 weeks. Started Nov 2016; status: completed.
02
Drugs
asivatrep
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02965118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965118.